HC Wainwright reaffirmed their buy rating on shares of Lipocine (NASDAQ:LPCN) in a research report report published on Wednesday, AnalystRatings.com reports. HC Wainwright currently has a $5.00 price target on the specialty pharmaceutical company’s stock.
“Valuation and risk. Our $5 target includes $3/share DCF value for Tlando oral TRT for hypogonadism, plus a $2/share value for the LPCN-1144 NASH opportunity. Our Tlando DCF still reflects just a 30% probability of success, 13% WACC discount rate and 2% terminal growth beyond 2024. Our model reflects late-2019 Tlando approval, a commercial partnership, 2020 launch, and peak partner sales over $300M generating over $75M annual royalty revenue to Lipocine.”,” HC Wainwright’s analyst commented.
Separately, LADENBURG THALM/SH SH reissued a buy rating on shares of Lipocine in a research note on Thursday, January 17th.
Shares of LPCN stock opened at $1.87 on Wednesday. The company has a current ratio of 5.37, a quick ratio of 5.37 and a debt-to-equity ratio of 0.49. Lipocine has a 1-year low of $1.04 and a 1-year high of $2.64.
Lipocine (NASDAQ:LPCN) last announced its earnings results on Wednesday, May 8th. The specialty pharmaceutical company reported ($0.14) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.01. Analysts forecast that Lipocine will post -0.75 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. purchased a new position in shares of Lipocine in the first quarter valued at approximately $37,000. Acadian Asset Management LLC purchased a new position in shares of Lipocine in the first quarter valued at approximately $41,000. Spark Investment Management LLC purchased a new position in shares of Lipocine in the first quarter valued at approximately $118,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of Lipocine in the first quarter valued at approximately $256,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Lipocine by 101.7% in the first quarter. Renaissance Technologies LLC now owns 406,700 shares of the specialty pharmaceutical company’s stock valued at $939,000 after purchasing an additional 205,100 shares during the period. 10.50% of the stock is owned by institutional investors and hedge funds.
Lipocine Company Profile
Lipocine Inc, a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability.
Featured Article: NASDAQ
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.